Key result
Ivabradine resulted in a non-significant reduction in the primary composite endpoint of cardiovascular death or hospital admission for worsening heart failure compared to placebo (20.5% vs 29.1%, HR 0.67).
Why the study?
Following demonstrated benefits of ivabradine in the SHIFT study, its efficacy and safety required evaluation in Japanese HFrEF patients.
Does ivabradine reduce the composite of cardiovascular death or hospital admission for worsening heart failure in Japanese patients with HFrEF?
RCT (n=254)
Double-blind
1:1
Yes
Does ivabradine reduce the composite of cardiovascular death or hospital admission for worsening heart failure in Japanese patients with HFrEF?
No significant benefit on primary endpoint; leaves open possible efficacy in Japanese HFrEF patients.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tsutsui et al. (2019) conducted an RCT in Chronic heart failure with reduced ejection fraction (HFrEF) (n=254). Ivabradine vs. Placebo was evaluated on Composite of cardiovascular death or hospital admission for worsening heart failure (HR 0.67, 95% CI 0.40-1.11, p=0.1179). Ivabradine resulted in a non-significant reduction in the primary composite endpoint of cardiovascular death or hospital admission for worsening heart failure compared to placebo (20.5% vs 29.1%, HR 0.67).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: